Vaccine News and Research

Latest Vaccine News and Research

Henry Schein net sales increase 4.9% to $2.5 billion in fourth quarter 2013

Henry Schein, Inc., the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, today reported record financial results for the quarter ended December 28, 2013.

11 Feb 2014

Unvaccinated flu patients need more intensive care

A snapshot of patients who required care at Duke University Hospital during this year's flu season shows that those who had not been vaccinated had severe cases and needed the most intensive treatment.

11 Feb 2014

Finding could lead to first effective vaccine against respiratory syncytial virus

Vanderbilt University scientists have contributed to a major finding, reported today in the journal Nature, which could lead to the first effective vaccine against respiratory syncytial virus (RSV), a significant cause of infant mortality.

9 Feb 2014

Viewpoints: CBO report on health law: Damaging the labor market or freeing workers from 'insurance trap'?

There are 7.8 million Americans working part-time who want full-time work, including a fry cook whose restaurant cut his hours to avoid Affordable Care Act mandates and confronted President Obama in an online Google Q&A last week: "We can't survive. It's not a living." Mr. Obama changed the subject to raising the minimum wage. But he can't dodge reality forever as the evidence piles up that ObamaCare is harming the labor market.

6 Feb 2014

TSRI scientists design artificial proteins as a candidate vaccine against RSV

Scientists at The Scripps Research Institute (TSRI) have invented a new method for designing artificial proteins, and have used it to make key ingredients for a candidate vaccine against a dangerous virus, respiratory syncytial virus (RSV), a significant cause of infant mortality.

6 Feb 2014

Researchers design new vaccine for human-infecting respiratory syncytial virus

Vaccines are the safest, cheapest and most effective way to protect against infectious diseases. But to make a good one is still a challenge, and traditional approaches are now stretched to the limit while fatal diseases, like HIV and malaria, remain without vaccine.

6 Feb 2014

Fraunhofer USA receives FDA clearance for IND malaria TBV that targets Pfs25 antigen

Fraunhofer USA Center for Molecular Biotechnology (FhCMB) announced today that clearance was obtained from the U.S. Food and Drug Administration (FDA) for an investigational new drug (IND), Fraunhofer's plant-derived malaria transmission-blocking vaccine (TBV), which targets the Pfs25 antigen, to proceed into the clinic in a Phase 1 safety and immunogenicity study.

5 Feb 2014

95% of adults die annually from vaccine preventable diseases

While adults make up 95 percent of those who die annually from vaccine preventable diseases, a new study from the University of Colorado School of Medicine shows their vaccination rates remain stubbornly low, representing a growing public health concern.

5 Feb 2014

First Edition: February 4, 2014

Today's headlines include progress reports on health exchanges in Washington state and New York as well as poll results on Virginia's Medicaid Expansion.

4 Feb 2014

Discovery may have implications for HIV vaccine research

NIH scientists have discovered a mechanism involved in stabilizing key HIV proteins and thereby concealing sites where some of the most powerful HIV neutralizing antibodies bind, findings with potential implications for HIV vaccine research.

4 Feb 2014

Admedus' HSV-2 therapeutic vaccine achieves primary endpoint in Phase 1 trial

Admedus today announced that interim study results on its Phase 1 trial of a therapeutic vaccine for Herpes Simplex Virus (HSV-2) have shown that it achieved the primary endpoint of the study by being safe in the study subjects. In addition, the study has also shown that the vaccine was able to generate a T-cell response.

3 Feb 2014

Teen girls' beliefs regarding HPV vaccine not linked to subsequent sexual behaviors

A new study may alleviate concerns that the human papillomavirus (HPV) vaccine leads to either the initiation of sex or unsafe sexual behaviors among teenage girls and young women.

3 Feb 2014

Keystone Symposia to convene conference focusing on the science of malaria eradication

Keystone Symposia, in collaboration with MESA (Malaria Eradication Scientific Alliance), is convening its first conference in Mexico – on "The Science of Malaria Eradication" at the Fiesta Americana Hotel in Merida, Yucatan. The four-day conference begins Sunday evening, February 2, 2014 and is part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation, which has also funded travel awards for investigators from malaria-endemic countries to attend. The conference will gather experts from 37 countries.

31 Jan 2014

Novel approaches could lead researchers to develop new vaccine for East Coast fever, malaria

The Nairobi-based International Livestock Research Institute announced today that a global consortium supported by the Bill & Melinda Gates Foundation has been formed to develop a new vaccine against a disease that's devastating cattle herds in sub-Saharan Africa. This highly advanced cattle vaccine project could also help malaria and cancer research in humans.

31 Jan 2014

Vaccine to treat precancerous cervical lesions triggers immune cell response

Preliminary results of a small clinical trial show that a vaccine used to treat women with high-grade precancerous cervical lesions triggers an immune cell response within the damaged tissue itself.

30 Jan 2014

NIBIO signs collaboration agreement for clinical development of new mucosal TB vaccines

Japan's National Institute of Biomedical Innovation ("NIBIO"), Aeras and Create Vaccine Company, Ltd ("CREATE") announce today that they signed a collaboration agreement on December 26, 2013, on the preclinical and clinical development of new mucosal tuberculosis (TB) vaccines based on NIBIO's human parainfluenza type-2 (rhPIV2) vector technology.

27 Jan 2014

TSRI professor wins 2014 Wolf Prize in chemistry

Chi-Huey Wong, professor of chemistry at The Scripps Research Institute (TSRI), has won the 2014 Wolf Prize in Chemistry for his pioneering contributions to the synthesis of compounds vitally important to biology and medicine.

25 Jan 2014

Clinical trial of experimental vaccine targets cancer stem cells in patients with recurrent brain tumor

An early-phase clinical trial of an experimental vaccine that targets cancer stem cells in patients with recurrent glioblastoma multiforme, the most common and aggressive malignant brain tumor, has been launched by researchers at Cedars-Sinai's Department of Neurosurgery, Johnnie L. Cochran, Jr. Brain Tumor Center and Department of Neurology.

25 Jan 2014

OBGYN.net to present new research and topics related to cervical health

UBM Medica US announces that OBGYN.net, a leading online community for medical professionals specializing in women's health, will present new research and topics over the coming weeks related to cervical cancer and cervical health in honor of January being Cervical Health Awareness Month.

23 Jan 2014

Inovio Pharmaceuticals unveils new DNA-based cytokine immune activator

Inovio Pharmaceuticals, Inc. today unveiled that the company has developed a new DNA-based cytokine immune activator, interleukin -33 (IL-33), that in combination with optimized DNA vaccines delivered by electroporation increased the potency and efficacy of the therapeutic response to the DNA vaccines in a preclinical study.

23 Jan 2014